Fact CheckerSign in

NCT06730035Active, not recruiting

PRediction of Outcomes and PERsonalized Radiotherapy by Biomarkers and Functional Imaging

Source: ClinicalTrials.gov · Last updated 12 Dec 2024

Brief summary (registry, in English)

This is a study focused on analyses of peripheral blood (tissue study). The aim of the trial is to determine whether it is possible to predict early clinical and/or pathological responses after radiotherapy in the setting of neoadjuvant treatment for locally advanced rectal carcinomas, through qualitative and quantitative assessment of circulating extracellular vesicles in plasma and the microRNA (miRNA) contained within them. Extracellular vesicles are "clean-up" structures that collect various elements circulating in the blood, including fragments of DNA and RNA from tumor cells. Observing how these structures and their contents change with radiotherapy could provide early indications of the tumor's response to treatment. The trial seeks to answer the question: "Can the quantity of CD69+ vesicles in patients undergoing neoadjuvant radiotherapy predict their response early?" The trial is monocentric and plans to enroll approximately 30 patients. Participation in this trial does not offer direct benefits, as it involves only laboratory investigations without modifications to the usual diagnostic-therapeutic process for the condition considered. The collection of information is aimed at improving knowledge regarding extracellular vesicles. These vesicles could provide early insights into the response to neoadjuvant radiotherapy for locally advanced rectal tumors. In this way, subsequent therapeutic strategies can be personalized based on this response.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
30 (estimated)
First submitted
1 Dec 2024
Start date
1 Oct 2024
Primary completion date
31 May 2028
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT number
NCT06730035

What you commit to

  • Study type: Interventional
  • Planned participants: 30
  • From 1 Oct 2024 to the primary completion date, 31 May 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Contraindications to MRI, uncontrolled chronic intestinal diseases or pelvic infections

Other

  • Pregnancy and breastfeeding
  • Unwillingness to participate in follow-up

Who the study is looking for

  • Patients candidates for neoadjuvant RT, administered with hypofractionated-accelerated treatment, for locally advanced rectal tumors;
  • Age ≥ 18 years
  • Obtaining informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Coordinator of this site? Confirm its status
BolognaItalyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.